stockportfolio.pro
MapLight Therapeutics, Inc. (MPLT)
Healthcare · Biotechnology · NasdaqGS
MapLight Therapeutics, Inc. revenue & earnings — last 2 fiscal years
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Gross profit | — | — |
| Net income | $-77.58M | $-161.15M |
| Net margin | — | — |
Source: MapLight Therapeutics, Inc. SEC filings (10-K).
Explore 2 years of MapLight Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MPLT in your portfolio →
MapLight Therapeutics, Inc. financial history by metric
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
MapLight Therapeutics, Inc. — frequently asked questions
What is MapLight Therapeutics, Inc.'s revenue?
MapLight Therapeutics, Inc. (MPLT) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is MapLight Therapeutics, Inc. profitable?
No — MPLT reported a net loss of $-161.15M in fiscal 2025.
What is MPLT's P/E ratio?
MapLight Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does MapLight Therapeutics, Inc. have?
As of fiscal year 2025, MPLT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is MapLight Therapeutics, Inc.'s market cap?
MapLight Therapeutics, Inc. (MPLT) has a market capitalization of about $1.32B, based on the latest data in our nightly-refreshed cache.
When does MapLight Therapeutics, Inc.'s fiscal year end?
MPLT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from MapLight Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.